AbbVie increases dividend for 47th year in 2018
AbbVie will raise its dividend by more than 35 percent in Q1 of 2018. This follows a 10.9 percent dividend hike in Q4 of 2017. The year 2018 will mark the 47th consecutive annual dividend increase by this Dividend Aristocrat.
The cash dividend is payable May 15, 2018 to stockholders of record at the close of business on April 13, 2018. The new dividend for ABBV is 3.3%.
Since the company's inception in 2013, AbbVie has increased its dividend by 140 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. Abbvie's Humira medicine (for treatment of psoriasis and rheumatoid arthritis) is the world's best selling prescription medicine.
